Literature DB >> 34510236

Predictive Tool for Closure of Ductus Arteriosus with Pharmacologic or Surgical Treatment in Preterm Infants.

TaiXiang Liu1, Zheng Chen2, XiaoLu Ma2, LiPing Shi2.   

Abstract

To construct a model with the indices obtained by echocardiography to predict whether patent ductus arteriosus (PDA) was required to be treated with pharmacologic treatment or surgical ligation, we performed a prospective observational study, including all neonates with gestational age ≤ 30 weeks and assessed the hemodynamics of PDA by serial daily echocardiography examination at postnatal age of 0-12 h, 24 h, 48 h, and 72 h, respectively. The infants were classified in two groups based on whether they were treated with non-steroidal anti-inflammatory drugs (NSAIDs) and/or surgical ligation to close the PDA from the second week after birth. We compared the echocardiographic indices between the two groups and utilized the indices to construct a model to predict which premature infants' PDA requires intervention. The results showed that a total of forty-two preterm infants were enrolled in the study. 15 (35.7%) preterms were in the intervention group and 27 (64.3%) preterms were in the non-intervention group. Compared with the non-intervention group, the intervention group had a higher proportion of left ventricular volume overload and systemic shunt effect. In addition, the combined indicators of PDA size/weight > 3.2 mm/kg and LA/Ao > 1.4 at postnatal age of 72 h had a highest value to predict whether PDA requires intervention. These findings denoted that serial daily echocardiographic assessment can be useful in predicting whether a PDA will be closed with NSAIDs and/or surgical ligation in preterm infants with gestational age ≤ 30 weeks.Trial registration Number: IRB No. 2018-IRB-073. Date: 2018/09/21, retrospectively registered.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Echocardiographic assessment; Hemodynamically significant patent ductus arteriosus; Newborn; Patent ductus arteriosus; Preterm infants

Mesh:

Substances:

Year:  2021        PMID: 34510236      PMCID: PMC8435120          DOI: 10.1007/s00246-021-02731-w

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


Introduction

Patent ductus arteriosus (PDA) is a major cause of cardiovascular compromise during transition from fetal to neonatal circulation in premature infants [1]. PDA is usually accompanied by significant left-to-right shunt through the ductus arteriosus (DA) and can be confirmed by echocardiography. Clinical manifestations include systemic hypoperfusion and pulmonary hyperperfusion [2]. Furthermore, severe morbidities, such as acute kidney injury (AKI), pulmonary hemorrhage, intraventricular hemorrhage (IVH), necrotizing enterocolitis (NEC), bronchopulmonary dysplasia (BPD), and increased mortality, are associated with PDA [3-7]. Conventionally, treatment options for PDA include the administration of non-steroidal anti-inflammatory drugs (NSAIDs) and/or surgical ligation if conservative treatment fails in premature infants. However, there are few consensus on the management of PDA, including whether, when, and how to treat, and few clinical studies on early serial daily echocardiographic assessment of the hemodynamics of PDA to predict whether pharmacologic or surgical treatment are required in the very preterm infants. Therefore, we performed this study to assess the characteristics of DA, indices of pulmonary overcirculation, and systemic shunt effect continuously and dynamically and constructed a model with echocardiographic indices to predict the probability of PDA that ultimately requires intervention.

Methods

With the approval of the Ethics Committee of the Children’s Hospital, Zhejiang University School of Medicine (IRB No. 2018-IRB-073), a prospective observational study was conducted to investigate the clinical data and echocardiographic indices of 42 preterm infants born at gestational age (GA) ≤ 30 weeks who were admitted to the neonatal intensive care unit of the Children’s Hospital, Zhejiang University School of Medicine from October 2018 to December 2020. Written informed consent was obtained from guardian participants. The exclusion criteria for this study were as follows: (1) the age at admission was > 12 h after birth; (2) infants who died or gave up treatment within 72 h of life; (3) infants complicated with complex congenital heart disease except for a small patent foramen ovale (PFO)/atrial septal defect (ASD)/ventricular septal defect (VSD); (4) the parents refused. In this study, we divided the patients into intervention group and non-intervention group according to whether PDA was treated or not during hospitalization: (1) intervention group: closure with oral non-steroidal anti-inflammatory drugs (NSAIDs) and/or surgical ligation; (2) non-intervention group: spontaneous closure without pharmacologic or surgical treatment. The indications for treatment were based on whether PDA was symptomatic including respiratory compromise (e.g., requiring persistent mechanical support), cardiac insufficiency, or large left-to-right ductus shunt with evidence of hemodynamic compromise, such as reversal of flow in the descending aorta during diastole, feeding intolerance, oliguria, hypotension, or wide pulse pressure in the study. Pharmacologic treatment was considered if conservative measures have failed to control the above symptoms from the second week after birth. PDA surgical ligation was generally performed in the patients which NSAIDs treatment was unsuccessful after the end of the two course or contraindicated. Transthoracic echocardiography was performed using GE Vivid™ iq bedside ultra-portable Doppler diagnostic ultrasound system with a 12S-RS transducer (GE Healthcare). We routinely assessed cardiac function (EF, FS, E:A, and E:E’), PDA characteristics (patency, dimension), indices of left heart volume ((LA:Ao, left ventricular end-diastolic diameter (LVEDd), end-diastolic velocity of the left pulmonary artery (LPA), left ventricular output (LVO)) and pressure (mitral valve E:A) loading, and the presence of retrograde diastolic blood flow in a post-ductal artery (descending aorta, DAo) in participants at postnatal age of 0–12 h, 24 h, 48 h, and 72 h, respectively. The serial daily echocardiographic assessments were performed by the same neonatologist who had received the training of critical ultrasound course. The data of patients’ demographics and clinical outcomes were recorded.

Statistical Analysis

Statistical analysis was performed using the SPSS version 21.0 and GraphPad Prism 7.00. We compared the echocardiographic data of the intervention group and the non-intervention group. Statistical analysis was performed using t test and Mann–Whitney u tests for continuous variables according to whether variables obey normal distribution or not. Χ2 or Fisher exact tests were used for categorical variables as appropriate. Data were expressed as median with quartile range (M (Q1, Q3)) for continuous variables or as a percentage of patients in a given categorical variable. All probability (p) values were two-tailed and a value less than 0.05 was considered statistically significant. Univariate and multivariate regression analyses were used to analyze the data variables of echocardiography to determine predictors of PDA requiring NSAIDs intervention and/or surgical ligation. Multivariable logistic regression analysis was performed to analyze the variables at postnatal age of 0–12 h, 24 h, 48 h, and 72 h, respectively, which using stepwise logistic regression with forward selection and backward elimination by removing variables that had a p value of greater than 0.05. Results were expressed as OR with 95%CI. The predictive power of multivariable model was evaluated by the receiver operating characteristic (ROC) curve and the area under the curve (AUC). Based on the results of the multivariable regression analysis, which the largest AUC was chosen. Cut-off values of the results were chosen on the basis of the ROC curve of each variable and outcome, which located in the maximum value of Youden Index according to the sensitivity and specificity.

Results

A total of forty-two very preterm infants met the inclusion criteria and were enrolled during the study period (Fig. 1). These were categorized into two groups: 15 (35.7%) in the intervention group: gestational age (GA) was 27.2 ± 1.1 weeks and birth weight ranged from 750 to 960 g (median 880 g) and 27 (64.3%) in the non-intervention group: GA was 28.8 ± 1.5 weeks and birth weight ranged from 950 to 1340 g (median 1050 g). Compared with the non-intervention group, the intervention group had a higher proportion of alveolar surfactant use (p = 0.008), reintubation within 48 h from extubation (p = 0.047), duration of mechanical ventilation (p < 0.001), inhale oxygen days (p = 0.005), inotropes/vasopressors use (p < 0.001), extrauterine growth retardation (EUGR) (p = 0.029), IVH grade ≥ 3 (p = 0.016), and retinopathy of prematurity (ROP) (p = 0.004). The mortality and other clinical manifestations were not statistically significant between the two groups (Table 1).
Fig. 1

Flowchart of enrolled participants

Table 1

Comparison of the demographic and clinical characteristics of the study cohort

Intervention group (n = 15)Non-intervention group (n = 27)p Value
Clinical Characters
 Male gender10(66.7%)17(63%)0.81
 Gestational age, weeks*27.2 ± 1.128.8 ± 1.50.001
 Birth weight, g*880(750–960)1050(950–1340)0.001
 Use of surfactant*13(86.7%)12(44.4%)0.008
 Reintubation within 48 h from extubation *4(26.7%)1(3.7%)0.047
 Duration of mechanical ventilation*25.7 ± 20.53.6 ± 6.1 < 0.001
 Non-invasive ventilation30.7 ± 18.920 ± 17.10.068
 Inhale oxygen days*70.5 ± 36.638.1 ± 32.40.005
 BPD14(93.3%)17(63%)0.075
 VAP/Lower respiratory infection8(53.3%)9(33.3%)0.206
 Late onset sepsis8(53.3%)9(3.3%)0.206
 Use of inotropes/vasopressors*10(66.7%)2(7.4%) < 0.001
 Feeding intolerance14(93.3%)17(63%)0.075
 Total enteral feeding45(39–70)38(20–65)0.27
 PNAC5(33.3%)7(25.9%)0.879
 EUGR*9(60%)7(25.9%)0.029
 ROP*10(66.7%)6(22.2%)0.004
 Length of hospital stay88(62–100)60(44–77)0.059
Complications and mortality
 NEC any stage2(13.3%)5(18.5%)1.000
 Pulmonary hemorrhage5(33.3%)2(7.4%)0.077
 IVH grade ≥ 3*5(33.3%)1(3.7%)0.016
 Death3(20%)2(7.4%)0.329

BPD Bronchopulmonary dysplasia, VAP Ventilator-associated pneumonia, PNAC Parenteral nutrition-associated cholestasis, EUGR Extrauterine growth retardation, ROP Retinopathy of prematurity, NEC Necrotizing enterocolitis, IVH Intraventricular hemorrhage

*Indicates parameters found to be statistically significant (p < 0.05)

Flowchart of enrolled participants Comparison of the demographic and clinical characteristics of the study cohort BPD Bronchopulmonary dysplasia, VAP Ventilator-associated pneumonia, PNAC Parenteral nutrition-associated cholestasis, EUGR Extrauterine growth retardation, ROP Retinopathy of prematurity, NEC Necrotizing enterocolitis, IVH Intraventricular hemorrhage *Indicates parameters found to be statistically significant (p < 0.05) The diameter of the DA in preterm infants of the intervention group increased gradually within 72 h after birth, while the trend in the non-intervention group was completely opposite. Compared with the non-intervention group, the diameters of DA at postnatal age of 0–12 h, 24 h, 48 h, and 72 h in the intervention group were larger, with significant statistical difference (p = 0.028, p < 0.001, p < 0.001, and p < 0.001, respectively). In addition, two groups had statistically significant difference compared with echocardiographic indices of pulmonary overcirculation, including LVO at postnatal age of 24 h, 48 h, and 72 h (p = 0.001, p = 0.007, and p = 0.002, respectively), LA/Ao at postnatal age of 72 h (p < 0.001), and end-diastolic flow of the LPA at 24 h, 48 h, and 72 h (p = 0.026, p < 0.001, and p < 0.001, respectively). The presence of retrograde diastolic blood flow of the DAo represents an index of systemic shunt effect. The incidence of diastolic reverse flow of the DAo was 26.7%, 80%, and 86.7% at postnatal age of 24 h, 48 h, and 72 h, respectively, in the intervention group, which were significantly higher than those of the non-intervention group (0.0%, 14.8%, and 18.5%, p = 0.012, p < 0.001, and p < 0.001, respectively). The other parameters of left ventricular systolic and diastolic function except for mitral valve E/E′ at the postnatal age of 72 h (p = 0.014) were not statistically significant between the two groups (Table 2).
Table 2

Comparison of the ultrasound parameter of the study cohort

Intervention group(n = 15)Non-intervention group (n = 27)p Value
Variables at postnatal age of 0–12 h
 EF67.8 ± 6.565 ± 8.20.263
 FS35(31–37)33(27–36)0.193
 E/A0.88 ± 0.190.8 ± 0.110.157
 E/E’11.5(9.3–17)9.7(7.8–13.7)0.253
 PDA size/weight(mm/kg)*2.6 ± 0.72.1 ± 0.70.028
 LVO(ml/kg.min)190.4(149.1–199.7)168.1(144.5–186.4)0.265
 LVEDd(mm)1.1(1–1.3)1.2(1.1–1.4)0.105
 LA/Ao1.3(1.2–1.4)1.4(1.3–1.5)0.109
 LPA(m/s)0.17(0.1–0.22)0.13(0.1–0.21)0.937
 DAo00
Variables at postnatal age of 24 h
 EF67.1 ± 10.264.9 ± 9.30.466
 FS32(28–39)32(27–38)0.608
 E/A0.88(0.8–1.1)0.84(0.78–0.9)0.168
 E/E’14.8(8.8–16.3)10.3(9.3–12.3)0.074
 PDA size/weight(mm/kg)*3.1 ± 0.81.8 ± 0.9 < 0.001
 LVO(ml/kg.min)*282.8 ± 71.4202.9 ± 30.40.001
 LVEDd(mm)1.21 ± 0.131.26 ± 0.20.401
 LA/Ao1.4(1.3–1.6)1.4(1.3–1.6)0.631
 LPA(m/s)*0.21(0.15–0.23)0.12(0.1–0.18)0.026
 DAo*4(26.7%)0(0.0%)0.012
Variables at postnatal age of 48 h
 EF69.4 ± 4.667.7 ± 7.70.368
 FS9.7(7.8–13.7)34.6 ± 5.30.591
 E/A0.87(0.78–1.1)0.87(0.8–0.95)0.979
 E/E’13.3(7.6–19.3)9.5(8–12.7)0.185
 PDA size/weight(mm/kg)*3.4 ± 0.91.6 ± 1.1 < 0.001
 LVO(ml/kg.min)*313.2 ± 90.9234.9 ± 58.20.007
 LVEDd(mm)1.27 ± 0.171.31 ± 0.220.563
 LA/Ao1.5 ± 0.11.5 ± 0.20.055
 LPA(m/s)*0.24(0.2–0.26)0.12(0.09–0.2) < 0.001
 DAo*12(80%)4(14.8%) < 0.001
Variables at postnatal age of 72 h
 EF70.5 ± 7.367.1 ± 7.90.183
 FS36.7 ± 6.134.3 ± 5.90.230
 E/A0.92 ± 0.20.85 ± 0.110.227
 E/E’*16.2 ± 7.311.7 ± 4.00.014
 PDA size/weight(mm/kg)*3.6(3.2–3.8)1.5(0–2.1) < 0.001
 LVO(ml/kg.min)*343.8 ± 89.1251.3 ± 57.80.002
 LVEDd(mm)1.31 ± 0.181.3 ± 0.20.879
 LA/Ao*1.6(1.5–1.7)1.3(1.2–1.5) < 0.001
 LPA(m/s)*0.24(0.22–0.26)0.12(0.1–0.2) < 0.001
 DAo*13(86.7%)5(18.5%) < 0.001

*Indicates parameters found to be statistically significant (p < 0.05)

Comparison of the ultrasound parameter of the study cohort *Indicates parameters found to be statistically significant (p < 0.05)

Risk Factors for PDA that Need Pharmacologic and/or Surgical Ligation Intervention Analyzed by Logistic Regression Analysis

There were fourteen statistically significant variables (one variable at postnatal age of 0–12 h, three variables at postnatal age of 24 h, four variables at postnatal age of 48 h, and six variables at postnatal age of 72 h) according to univariable logistic regression analysis where PDA requiring NSAIDs intervention and/or surgical ligation was used as the dependent variable, while each continuous variable and categorical variable was used as the independent variable (Tables 3, 4, 5, 6). For the variables that showed no statistically significant difference, but were proven in previous trials, they were still included in the multivariate regression analysis. We, respectively, conducted four times multivariate regression analysis according to the time period of ultrasound screening and the variables included EF, E/E’, PDA size/weight, LVO, LA/Ao, LVEDd, end-diastolic flow of the LPA, and retrograde diastolic blood flow of DAo in each regression analysis model. There was only one statistically significant variable in the first three models (PDA size/weight at 0–12 h, LVO at 24 h, PDA size/weight at 48 h) and two statistically significant variables (PDA size/weight at 72 h and LA/Ao at 72 h) in the fourth model, with backward selection were retained in each model (Table 7). The ROC of the four models was drawn with the variables and outcome, and the area under curve (AUC) was 0.731 (95%CI 0.57–0.89, p = 0.014), 0.877 (95%CI 0.75–1, p < 0.001), 0.915 (95%CI 0.83–1, p < 0.001), and 0.958 (95%CI 0.9–1, p < 0.001), respectively (Fig. 2). The largest AUC was seen in the combined indicators of PDA size/weight and LA/Ao at postnatal age of 72 h in the fourth model. Cut-off values of the variables were 3.2 mm/kg and 1.4 for PDA size/weight and LA/Ao, respectively, with sensitivity and specificity of 100% and 88.9%, respectively.
Table 3

Results of univariate regression analysis of variables at postnatal age of 0–12 h

VariablesβSEWalddfp ValueOR95%CI
LowerUpper
EF0.0500.0441.27610.2591.0510.9641.146
FS0.0490.0590.69010.4061.0500.9361.178
E/A3.9232.4522.55910.1150.5270.4136174.457
E/E’0.0730.0621.37210.2421.0750.9521.214
PDA size /weight (mm/kg)*1.0230.4964.24810.0392.7821.0527.360
LVO(ml/kg.min)0.0100.0081.38210.2401.0100.9941.026
LVEDd(mm)− 3.2162.0962.35510.1250.040.0012.439
LA/Ao− 3.4962.2022.52010.1120.030.0002.271
LPA(m/s)0.7365.4200.01810.8922.0880.00085,762.875

*Indicates parameters found to be statistically significant (p < 0.05)

Table 4

Results of univariate regression analysis of variables at postnatal age of 24 h

VariablesβSEWalddfp ValueOR95%CI
LowerUpper
EF0.0250.0340.55510.4561.0260.9591.097
FS0.0320.0440.53410.4651.0330.9481.125
E/A4.7072.5583.38810.066110.7550.73716,646.885
E/E’0.1070.0762.00910.1561.1130.961.291
PDA size /weight (mm/kg)*1.8410.6109.09910.0036.3051.90620.859
LVO(ml/kg.min)*0.0490.0168.90610.0031.0501.0171.084
LVEDd(mm)− 1.5541.8190.73010.3930.2110.0067.475
LA/Ao1.1041.9690.31410.5753.0170.064143.194
LPA(m/s)9.9205.4073.36710.06720,333.2990.508813,311,747.2
DAo*22.10120,096.4850.00010.9993,965,256,4850.000

*Indicates parameters found to be statistically significant (p < 0.05)

Table 5

Results of univariate regression analysis of variables at postnatal age of 48 h

VariablesβSEWalddfp ValueOR95%CI
LowerUpper
EF0.0400.0500.63810.4241.0410.9431.149
FS0.0380.0690.30410.5821.0390.9071.190
E/A2.0352.4440.69310.4057.6530.064920.505
E/E’0.0570.0551.06210.3031.0590.951.18
PDA size/weight (mm/kg)*1.7770.5699.75210.0025.912193818.036
LVO(ml/kg.min)*0.0150.0067.20910.0071.0151.0041.026
LVEDd(mm)− 0.9921.6730.35210.5530.3710.0149.832
LA/Ao4.3702.3383.49410.06279.0690.8097730.881
LPA(m/s)*26.0877.96810.71810.0012.135E + 1135,219.8331.294E + 18
DAo*− 3.1350.84313.84410.00023.0004.410119.960

*Indicates parameters found to be statistically significant (p < 0.05)

Table 6

Results of univariate regression analysis of variables at postnatal age of 72 h

VariablesβSEWalddfp ValueOR95%CI
LowerUpper
EF0.0590.0451.77310.1831.0610.9721.158
FS0.0680.0561.45910.2271.0710.9581.196
E/A3.1202.2211.97210.1622.6390.2911760.625
E/E’*0.1600.0724.89310.0271.1741.0181.352
PDA size/weight (mm/kg)*1.8960.5 9210.27010.0016.6612.08921.242
LVO(ml/kg.min)*0.0170.0068.77810.0031.0171.0061.029
LVEDd(mm)0.2651.6910.02510.8751.3030.04735.817
LA/Ao*7.0772.2579.83210.0021183.94214.19998,717.018
LPA(m/s)*18.0386.2708.27610.00468,217,631.55313.7261.483E + 13
DAo*3.3530.90713.67410.00028.6004.836169.153

*Indicates parameters found to be statistically significant (p < 0.05)

Table 7

Multivariable predictors of PDA that need to be treated with NSAIDs and/or surgical ligation in the predictive models

ModelVariablesβSEWalddfp ValueOR95%CI
LowerUpper
Model 1PDA size/weight at 0-12 h(mm/kg)1.023.4964.24810.0392.7821.0527.360
Intercept− 3.0121.2435.87310.0150.049
Model 2LVO at 24 h(ml/kg.min).049.0168.90610.0031.0501.0171.084
Intercept− 11.8623.8009.74510.0020.000
Model 3PDA size/weight at 48 h(mm/kg)1.7770.5699.75210.0025.9121.93818.036
Intercept− 5.0361.56610.33810.0010.007
Model 4PDA size/weight at 72 h(mm/kg)1.876.6498.35710.0046.5301.83023.305
LA/Ao at 72 h8.1994.0324.13410.0423635.7791.3439,839,607.803
Intercept− 18.2807.3446.19610.0080.000
Fig. 2

Receiver operating characteristic curves (ROC) for predicting PDA that need to be treated with NSAIDs and/or surgical ligation. Curve A: PDA size/weight at postnatal age of 0-12 h; curve B: LVO at postnatal age of 24 h; curve C: PDA size/weight at postnatal age of 48 h; curve D: PDA size/weight and LA/Ao at postnatal age of 72 h

Results of univariate regression analysis of variables at postnatal age of 0–12 h *Indicates parameters found to be statistically significant (p < 0.05) Results of univariate regression analysis of variables at postnatal age of 24 h *Indicates parameters found to be statistically significant (p < 0.05) Results of univariate regression analysis of variables at postnatal age of 48 h *Indicates parameters found to be statistically significant (p < 0.05) Results of univariate regression analysis of variables at postnatal age of 72 h *Indicates parameters found to be statistically significant (p < 0.05) Multivariable predictors of PDA that need to be treated with NSAIDs and/or surgical ligation in the predictive models Receiver operating characteristic curves (ROC) for predicting PDA that need to be treated with NSAIDs and/or surgical ligation. Curve A: PDA size/weight at postnatal age of 0-12 h; curve B: LVO at postnatal age of 24 h; curve C: PDA size/weight at postnatal age of 48 h; curve D: PDA size/weight and LA/Ao at postnatal age of 72 h

Discussion

Previous studies have demonstrated that PDA is associated with many early and late adverse outcomes [3-7]. In the present study, we identified an inverse relationship between the need for drug treatment and/or ligation in PDA and gestational age and birth weight. The DA left-to-right shunt can result in an interstitial and alveolar pulmonary edema and decreased lung compliance, which leads to higher ventilator settings prolonged ventilation with the period of oxygen inhalation, and increased risk of pulmonary hemorrhage and BPD [8, 9]. RDS will also aggravate this process as a result of low plasma oncotic pressure and increased capillary permeability, as confirmed by a previous study [10]. Our study shows that the preterm infants in the PDA intervention group required more pulmonary surfactant, longer mechanical ventilation, and oxygen demand. However, there was no significant difference in the incidence of pulmonary hemorrhage and BPD between the intervention group and non-intervention groups. This may be attributed to the small sample size used in our study. Furthermore, the presence of a PDA can result in systemic hypoperfusion that is associated with several morbidities, including hypotension and IVH, as confirmed by our study [4, 5, 10, 11]. Worthy of note is the fact that a significant shunt through the DA may remain clinically “silent” during the first few days of life [2, 12]. This is demonstrated in our study where a lack of clinical evidence of hsPDA in the intervention group was accompanied by significant pulmonary overcirculation and systemic shunt effect within 72 h after birth, as identified using ultrasound indicators. Therefore, we used a combination of echocardiographic indices to construct a predictive model of PDA with a sensitivity and specificity of 100% and 88.9%, respectively. Consequently, our predictive model was helpful in predicting high risk of PDA requiring NSAIDs intervention and/or surgical ligation. Transductal diameter has been identified as the most commonly used hsPDA indicator. Several clinical studies have identified transductal diameter as a risk factor for developing PDA [2, 13–15]. Transductal shunt volume is largely determined by the dimension of the shunt [16]. Clinical investigators have classified absolute PDA diameter into small (< 1.5), moderate (1.5–2.0), and large (≥ 2.0), respectively [17]. In the present study, we measured the diameter of ductus at its narrowest point corresponding to the pulmonary artery end, by direct view or color Doppler, and chose the ratio of diameter to patient’s weight as the variable, instead of an absolute value. This option was considered because of the significant difference in birth weight between the two groups in this study. In a previous study, L Storme found that the PDA size/weight  > 1.4 mm/kg measured within 48 h after birth is a good indicator of hsPDA [18]. In addition, Kwinta reported that a PDA size/weight > 1.5 mm/kg measured 12–48 h after birth is a predictive index for PDA requiring surgical ligation [19]. Furthermore, Harling used PDA size/weight ≥ 2 mm/kg measured at 72 h of age as the predictive index for PDA requiring treatment [15]. However, our study found that PDA size/weight > 3.2 mm/kg at postnatal age of 72 h could be used as a predictive factor for infants with PDA requiring oral NSAIDs treatment and/or surgical ligation. A large amount of transductal left-to-right shunt increases pulmonary blood flow and pulmonary venous return. Consequently, this increases the left-side heart volume loading, leading to dilatation of the left atrium and ventricle from increased preload, especially in the absence of a large intra-atrial shunt during the cardiovascular transition stage [20]. Hence, a ratio of LA/Ao can be used as a surrogate index of pulmonary overcirculation and hsPDA [21, 22]. Many previous clinical trials reported that LA/Ao ratio of > 1.5 is a predictor of hsPDA [2, 23, 24]. In our study, LA/Ao was obtained from the parasternal long-axis view using a plain 2D image and the final result is consistent with previous trials, demonstrating that LA/Ao > 1.4 at postnatal age of 72 h can be used as a risk factor for predicting PDA requiring treatment. Studies have demonstrated that LVO, which represents pulmonary blood flow, could be a predictive factor for hsPDA requiring intervention. High LVO value is often associated with a large left-to-right shunt through the PDA and pulmonary overcirculation [25]. A previous study reported that a cut-off of LVO > 300 ml/kg/min was associated with the clinical presence of hsPDA [2]. Another previous study demonstrated that the ratio of the LVO to superior vena cava flow is directly proportional to the ductus flow and, when ≥ 4, may indicate hemodynamic significance [26]. Our results show that LVO > 251.7 ml/kg.min at postnatal age of 24 h (sensitivity was 66.7%, specificity was 100%) could be used as a predictive factor for hsPDA requiring treatment. The limitations of the present study are as follows: firstly, the indices of pulmonary overcirculation, such as LVEDd, end-diastolic velocity of LPA and mitral valve E/A, and systemic shunt effect such as retrograde blood flow of descending aorta during the first few days after birth, could not be used as risk factors to predict the necessity of therapy for PDA in our study. This is inconsistent with the results of some previous reports [27-29]. This inconsistency may be related to our sample size and needs further investigation. Secondly, in our study, we only used echocardiography indices as a predictor for PDA and did not include these clinical characteristics such as gestational age, birth weight, and the severity of RDS in the multivariate regression analysis. Therefore, we are unable to determine whether there is a significant association between the need for PDA treatment and these clinical characteristics.

Conclusion

Serial daily echocardiographic assessment can be useful in predicting whether a PDA will be closed with NSAIDs and/or surgical ligation in preterm infants with gestational age ≤ 30 weeks.
  28 in total

1.  Diagnosis and Management of Patent Ductus Arteriosus.

Authors:  Maria Gillam-Krakauer; Jeff Reese
Journal:  Neoreviews       Date:  2018-07

2.  Can early echocardiographic findings predict patent ductus arteriosus?

Authors:  Przemko Kwinta; Andrzej Rudziński; Piotr Kruczek; Zbigniew Kordon; Jacek Józef Pietrzyk
Journal:  Neonatology       Date:  2008-09-06       Impact factor: 4.035

3.  Echocardiographic assessment of ductal significance: retrospective comparison of two methods.

Authors:  Manuela Condò; Nick Evans; Roberto Bellù; Martin Kluckow
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2011-05-05       Impact factor: 5.747

Review 4.  Functional Echocardiography in the Neonatal Intensive Care Unit.

Authors:  Yogen Singh; Anup Katheria; Cecile Tissot
Journal:  Indian Pediatr       Date:  2018-05-15       Impact factor: 1.411

5.  Relationship of Patent Ductus Arteriosus Size to Echocardiographic Markers of Shunt Volume.

Authors:  Fernando de Freitas Martins; Daniel Ibarra Rios; Maura Helena F Resende; Henna Javed; Dany Weisz; Amish Jain; Jose Maria de Andrade Lopes; Patrick J McNamara
Journal:  J Pediatr       Date:  2018-08-13       Impact factor: 4.406

6.  Interparametric correlation between echocardiographic markers in preterm infants with patent ductus arteriosus.

Authors:  Arvind Sehgal; Samuel Menahem
Journal:  Pediatr Cardiol       Date:  2013-01-31       Impact factor: 1.655

7.  Early echocardiographic prediction of symptomatic patent ductus arteriosus in preterm infants undergoing mechanical ventilation.

Authors:  M Kluckow; N Evans
Journal:  J Pediatr       Date:  1995-11       Impact factor: 4.406

8.  Morbidity and mortality in preterm neonates with patent ductus arteriosus on day 3.

Authors:  Anna Sellmer; Jesper Vandborg Bjerre; Michael Rahbek Schmidt; Patrick J McNamara; Vibeke Elisabeth Hjortdal; Bente Høst; Bodil Hammer Bech; Tine Brink Henriksen
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2013-07-26       Impact factor: 5.747

9.  Failure of ductus arteriosus closure is associated with increased mortality in preterm infants.

Authors:  Shahab Noori; Michael McCoy; Philippe Friedlich; Brianna Bright; Venugopal Gottipati; Istvan Seri; Kris Sekar
Journal:  Pediatrics       Date:  2009-01       Impact factor: 7.124

Review 10.  Application of NPE in the assessment of a patent ductus arteriosus.

Authors:  David van Laere; Bart van Overmeire; Samir Gupta; Afif El-Khuffash; Marilena Savoia; Patrick J McNamara; Christoph E Schwarz; Willem P de Boode
Journal:  Pediatr Res       Date:  2018-07       Impact factor: 3.756

View more
  1 in total

1.  [Timing of surgical ligation of patent ductus arteriosus in very low birth weight infants].

Authors:  Tai-Xiang Liu; Xiao-Lu Ma; Zheng Chen; Li-Ping Shi
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-05-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.